<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04131127</url>
  </required_header>
  <id_info>
    <org_study_id>CP2561-0316</org_study_id>
    <nct_id>NCT04131127</nct_id>
  </id_info>
  <brief_title>Sentinel Low Risk Registry</brief_title>
  <official_title>Cerebral Protection of Acute Embolic Burden During Transcatheter Aortic Valve Implantation in Low Risk Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CVPath Institute Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>CVPath Institute Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This registry is designed to quantify embolic debris capture rate in patients at low surgical
      risk treated with the Sentinel System during TAVI.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The SENTINEL-LIR Study is a multicenter, prospective registry to observe rate and type of
      debris capture in subjects at low surgical risk undergoing TAVI to demonstrate the positive
      effects of the use of the Sentinel System. Histopathology of captured debris from the
      Sentinel System will be analyzed.

      The primary objective is to determine the presence or absence of particles of 7 discreet
      tissue types: acute thrombus (with or without associated tissue/foreign material), organizing
      thrombus, valve tissue, arterial wall/necrotic core, calcification, foreign material, and
      myocardium. Morphometric assessment of the debris (sizes &gt;150 m, &gt;500 m, and &gt;1,000 m).

      Patients will be screened for inclusion and exclusion criteria and documents which will have
      been reviewed and approved by the local Ethics Committee or regulatory authority prior to
      undergoing any study related exams or procedures.

      Fifty (50) subjects will be enrolled in the study from an estimated 6 different sites.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 20, 2019</start_date>
  <completion_date type="Anticipated">May 20, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 20, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Day</target_duration>
  <primary_outcome>
    <measure>The SENTINEL-LIR Study</measure>
    <time_frame>12 months</time_frame>
    <description>To determine the incidence and type of debris capture in SENTINEL devices deployed during TAVI in patients at low surgical risk</description>
  </primary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>To Determine the Incidence and Type of Debris Capture in SENTINEL Devices Deployed During TAVI in Patients at Low Surgical Risk</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sentinel Device</intervention_name>
    <description>Sentinel Device used during TAVI in a Low Risk Patient</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      We will collect debris that have been captured in the Sentinel filter and perform pathology
      on those specimens
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study population is comprised of subjects with severe native aortic valve stenosis who
        meet the commercially approved indications for TAVI and comply with the inclusion/exclusion
        criteria described below.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Severe symptomatic aortic valve stenosis

          2. Planned use of Sentinel System

          3. Subject planned for transfemoral TAVI with valve system approved by U.S. FDA for low
             risk patients

          4. STS-PROM score of less than 4% and agreement by Heart Team that patients meet criteria
             for low surgical risk

        Exclusion Criteria:

          1. Current or recent cerebrovascular accident (stroke, TIA) &lt;6 months

          2. Transapical, direct aortic or subclavian TAVI access

          3. Carotid stenting or endarterectomy in last 6 weeks

          4. Prior aortic valve replacement

          5. Concomitant procedure with TAVI such as CABG, PCI, etc.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aloke V Finn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CVPath Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aloke V Finn, MD</last_name>
    <phone>301-208-3570</phone>
    <phone_ext>113</phone_ext>
    <email>afinn@cvpath.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamim M Nazif, MD</last_name>
      <phone>212-342-0444</phone>
      <email>tmn31@columbia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Rinaldi, MD</last_name>
      <phone>704-342-0332</phone>
      <email>Michael.Rinaldi@atriumhealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samir Samir Kapadia, MD</last_name>
      <phone>216-444-2273</phone>
      <email>KAPADIS@ccf.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UPMC Pinnacle</name>
      <address>
        <city>Wormleysburg</city>
        <state>Pennsylvania</state>
        <zip>17043</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hemal Gada, MD</last_name>
      <phone>717-731-0101</phone>
      <email>gadah@upmc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Seeger J, Kapadia SR, Kodali S, Linke A, Wöhrle J, Haussig S, Makkar R, Mehran R, Rottbauer W, Leon M. Rate of peri-procedural stroke observed with cerebral embolic protection during transcatheter aortic valve replacement: a patient-level propensity-matched analysis. Eur Heart J. 2019 May 1;40(17):1334-1340. doi: 10.1093/eurheartj/ehy847.</citation>
    <PMID>30590554</PMID>
  </reference>
  <reference>
    <citation>Schmidt T, Leon MB, Mehran R, Kuck KH, Alu MC, Braumann RE, Kodali S, Kapadia SR, Linke A, Makkar R, Naber C, Romero ME, Virmani R, Frerker C. Debris Heterogeneity Across Different Valve Types Captured by a Cerebral Protection System During Transcatheter Aortic Valve Replacement. JACC Cardiovasc Interv. 2018 Jul 9;11(13):1262-1273. doi: 10.1016/j.jcin.2018.03.001.</citation>
    <PMID>29976363</PMID>
  </reference>
  <reference>
    <citation>Lazar RM, Pavol MA, Bormann T, Dwyer MG, Kraemer C, White R, Zivadinov R, Wertheimer JC, Thöne-Otto A, Ravdin LD, Naugle R, Mechanic-Hamilton D, Garmoe WS, Stringer AY, Bender HA, Kapadia SR, Kodali S, Ghanem A, Linke A, Mehran R, Virmani R, Nazif T, Parhizgar A, Leon MB. Neurocognition and Cerebral Lesion Burden in High-Risk Patients Before Undergoing Transcatheter Aortic Valve Replacement: Insights From the SENTINEL Trial. JACC Cardiovasc Interv. 2018 Feb 26;11(4):384-392. doi: 10.1016/j.jcin.2017.10.041. Epub 2018 Feb 1.</citation>
    <PMID>29397361</PMID>
  </reference>
  <reference>
    <citation>Kapadia SR, Kodali S, Makkar R, Mehran R, Lazar RM, Zivadinov R, Dwyer MG, Jilaihawi H, Virmani R, Anwaruddin S, Thourani VH, Nazif T, Mangner N, Woitek F, Krishnaswamy A, Mick S, Chakravarty T, Nakamura M, McCabe JM, Satler L, Zajarias A, Szeto WY, Svensson L, Alu MC, White RM, Kraemer C, Parhizgar A, Leon MB, Linke A; SENTINEL Trial Investigators. Protection Against Cerebral Embolism During Transcatheter Aortic Valve Replacement. J Am Coll Cardiol. 2017 Jan 31;69(4):367-377. doi: 10.1016/j.jacc.2016.10.023. Epub 2016 Nov 1.</citation>
    <PMID>27815101</PMID>
  </reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 16, 2019</study_first_submitted>
  <study_first_submitted_qc>October 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2019</study_first_posted>
  <last_update_submitted>October 16, 2019</last_update_submitted>
  <last_update_submitted_qc>October 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

